Bristol Myers Squibb Company (NYSE:BMY) Holdings Raised by Kingswood Wealth Advisors LLC

Kingswood Wealth Advisors LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 57.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 77,071 shares of the biopharmaceutical company's stock after acquiring an additional 28,129 shares during the period. Kingswood Wealth Advisors LLC's holdings in Bristol Myers Squibb were worth $4,639,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth $26,000. Global Wealth Strategies & Associates grew its stake in Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares during the last quarter. Transce3nd LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth $28,000. Finally, Fairway Wealth LLC bought a new position in Bristol Myers Squibb during the 4th quarter worth $28,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Samit Hirawat bought 4,250 shares of Bristol Myers Squibb stock in a transaction dated Friday, April 25th. The stock was acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research note on Friday, April 25th. Cantor Fitzgerald restated a "neutral" rating and set a $55.00 price objective on shares of Bristol Myers Squibb in a research note on Tuesday, April 22nd. UBS Group lowered their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research note on Friday, April 11th. The Goldman Sachs Group restated a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol Myers Squibb in a research note on Tuesday, April 8th. Finally, Argus raised Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Price Performance

BMY stock traded down $0.41 during trading hours on Thursday, hitting $46.82. 15,848,711 shares of the stock traded hands, compared to its average volume of 12,966,606. The stock has a 50-day simple moving average of $48.28 and a 200 day simple moving average of $54.43. Bristol Myers Squibb Company has a one year low of $39.35 and a one year high of $63.33. The company has a market cap of $95.29 billion, a P/E ratio of 17.54, a P/E/G ratio of 1.39 and a beta of 0.38. The company has a current ratio of 1.28, a quick ratio of 1.17 and a debt-to-equity ratio of 2.65.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter last year, the business posted ($4.40) earnings per share. The company's quarterly revenue was down 5.6% on a year-over-year basis. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.30%. The ex-dividend date is Thursday, July 3rd. Bristol Myers Squibb's dividend payout ratio is 92.88%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.